Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy

  • Authors:
    • Xiao Song Chen
    • Jia Yi Wu
    • Ou Huang
    • Can Ming Chen
    • Jiong Wu
    • Jin Song Lu
    • Zhi Ming Shao
    • Zhen Zhou Shen
    • Kun Wei Shen
  • View Affiliations

  • Published online on: May 1, 2010     https://doi.org/10.3892/or_00000752
  • Pages: 1213-1220
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We investigated whether molecular subtype can predict the response and prognosis in Chinese locally advanced breast cancer (LABC) patients treated with preoperative therapy. LABC patients treated with preoperative therapy in Cancer Hospital, Fudan University between August 2001 and May 2008 were retrospectively analyzed. Molecular subtypes were constructed from the immunohistochemical results of hormonal receptors (HR) and HER2 status, which were classified as luminal (HR+/HER2−), triple negative (HR−/HER2−) and HER2 positive subtypes. Preoperative tumor parameters, chemotherapy regimens and response as well as outcome were compared among these subtypes. A total of 225 cases were included into analysis. Univariate and multivariate analysis showed that the pathological complete remission (pCR) independent predictive factors were molecular subtype and preoperative regimens. Compared with luminal subtype, patients with HER2 positive or triple negative tumor had significantly higher pCR rate, with odds ratio 3.02 (95% CI=1.07-8.07; P=0.037) and 3.10 (95% CI=1.01-9.52; P=0.048), respectively. However, HER2 positive or triple negative breast cancer patients were also associated with increased recurrence (P=0.072) and death rates (P=0.019) compared with luminal subtype in the whole population, and was especially worse in patients with residual disease after preoperative therapy with decreased disease-free survival (P=0.022) and overall survival (P=0.007). Our results show that molecular subtype can predict the response and prognosis of Chinese LABC patients treated with preoperative therapy. Compared with luminal subtype, patients with HER2 positive or triple negative disease had increased pCR rates, but associated with significantly worse survival, especially in those with residual disease after preoperative therapy.

Related Articles

Journal Cover

May 2010
Volume 23 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ and Shen KW: Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy. Oncol Rep 23: 1213-1220, 2010.
APA
Chen, X.S., Wu, J.Y., Huang, O., Chen, C.M., Wu, J., Lu, J.S. ... Shen, K.W. (2010). Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy. Oncology Reports, 23, 1213-1220. https://doi.org/10.3892/or_00000752
MLA
Chen, X. S., Wu, J. Y., Huang, O., Chen, C. M., Wu, J., Lu, J. S., Shao, Z. M., Shen, Z. Z., Shen, K. W."Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy". Oncology Reports 23.5 (2010): 1213-1220.
Chicago
Chen, X. S., Wu, J. Y., Huang, O., Chen, C. M., Wu, J., Lu, J. S., Shao, Z. M., Shen, Z. Z., Shen, K. W."Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy". Oncology Reports 23, no. 5 (2010): 1213-1220. https://doi.org/10.3892/or_00000752